FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031578702> ?p ?o ?g. }

• W3031578702 endingPage "5543" @default.
• W3031578702 startingPage "5543" @default.
• W3031578702 abstract "5543 Background: Initial evidence suggests activity of pembro + enza in patients (pts) resistant to enza. We present results from the multicohort phase II study KEYNOTE-199 (NCT02787005) in chemotherapy-naive pts with mCRPC treated with pembro + enza after progression with enza and who had RECIST-measurable (C4) or bone-predominant (C5) disease. Methods: Pts who did or did previously receive abiraterone and for whom enza treatment failed after clinically meaningful response received pembro 200 mg Q3W, with continuation of enza for up to 2 y or until progression, toxicity, or withdrawal. End point was ORR per RECIST v1.1 (C4) by blinded independent central review (primary); DOR (C4), time to PSA progression, rPFS, OS, and safety. Results: A total of126 pts (C4, 81; C5, 45) were treated. Median (range) PSA was 31 ng/mL (0.4-1667) in C4 and 19 ng/mL (1-1750) in C5.Median (range) time from enrollment to data cut off was 15 mo (7-21) in C4 and 19 mo (7-21) in C5. In C4, ORR (95% CI) was 12% (6-22; 2 CRs, 8 PRs) and median (range) DOR was 6 mo (3+ to 13); 60% of pts had DOR ≥6 mo. DCR (CR + PR + SD) was 51% in C4 and C5. Median (95% CI) time to PSA progression was 4 mo (4-4) in C4 and 4 mo (4-4) in C5. Median (95% CI) rPFS was 4 mo (3-6) for C4 and 4 mo (3-6) for C5; 12-mo rPFS rate was 17% in C4 and 23% in C5. Median (95% CI) OS was NR (16-NR) in C4 and 19 (14-NR) mo in C5; 12-mo OS rate was 70% in C4 and 75% in C5. Shorter median OS was more associated with prior enza treatment <6 mo than with prior enza treatment ≥6 mo. Liver metastasis was associated with shorter median OS however, median OS in visceral disease subgroups appeared longer than expected. Any-grade/grade ≥3 treatment-related AEs occurred in 75%/26% of pts in C4 and 69%/24% in C5. Two pts in C5 died of immune-related AEs (Miller Fisher syndrome and myasthenia gravis). Any-grade/grade 3/4 rash (regardless of relatedness) was higher than that in prior reports for individual agents (33%/6%). Conclusions: Pembro + enza after enza resistance had manageable safety and showed antitumor activity for RECIST-measurable and bone-predominant mCRPC. This combination is being evaluated in an ongoing phase III combination trial. Clinical trial information: NCT02787005 . [Table: see text]" @default.
• W3031578702 created "2020-06-05" @default.
• W3031578702 creator A5006249276 @default.
• W3031578702 creator A5007663088 @default.
• W3031578702 creator A5018645768 @default.
• W3031578702 creator A5019680927 @default.
• W3031578702 creator A5029369969 @default.
• W3031578702 creator A5039709555 @default.
• W3031578702 creator A5039922522 @default.
• W3031578702 creator A5041581270 @default.
• W3031578702 creator A5047806708 @default.
• W3031578702 creator A5057146540 @default.
• W3031578702 creator A5057407696 @default.
• W3031578702 creator A5059978899 @default.
• W3031578702 creator A5070016877 @default.
• W3031578702 creator A5073593424 @default.
• W3031578702 creator A5076098983 @default.
• W3031578702 creator A5079046653 @default.
• W3031578702 date "2020-05-20" @default.
• W3031578702 modified "2023-10-16" @default.
• W3031578702 title "KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W3031578702 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.5543" @default.
• W3031578702 hasPublicationYear "2020" @default.
• W3031578702 type Work @default.
• W3031578702 sameAs 3031578702 @default.
• W3031578702 citedByCount "14" @default.
• W3031578702 countsByYear W30315787022021 @default.
• W3031578702 countsByYear W30315787022022 @default.
• W3031578702 countsByYear W30315787022023 @default.
• W3031578702 crossrefType "journal-article" @default.
• W3031578702 hasAuthorship W3031578702A5006249276 @default.
• W3031578702 hasAuthorship W3031578702A5007663088 @default.
• W3031578702 hasAuthorship W3031578702A5018645768 @default.
• W3031578702 hasAuthorship W3031578702A5019680927 @default.
• W3031578702 hasAuthorship W3031578702A5029369969 @default.
• W3031578702 hasAuthorship W3031578702A5039709555 @default.
• W3031578702 hasAuthorship W3031578702A5039922522 @default.
• W3031578702 hasAuthorship W3031578702A5041581270 @default.
• W3031578702 hasAuthorship W3031578702A5047806708 @default.
• W3031578702 hasAuthorship W3031578702A5057146540 @default.
• W3031578702 hasAuthorship W3031578702A5057407696 @default.
• W3031578702 hasAuthorship W3031578702A5059978899 @default.
• W3031578702 hasAuthorship W3031578702A5070016877 @default.
• W3031578702 hasAuthorship W3031578702A5073593424 @default.
• W3031578702 hasAuthorship W3031578702A5076098983 @default.
• W3031578702 hasAuthorship W3031578702A5079046653 @default.
• W3031578702 hasConcept C121608353 @default.
• W3031578702 hasConcept C126322002 @default.
• W3031578702 hasConcept C143998085 @default.
• W3031578702 hasConcept C2776421732 @default.
• W3031578702 hasConcept C2776551883 @default.
• W3031578702 hasConcept C2780192828 @default.
• W3031578702 hasConcept C29456083 @default.
• W3031578702 hasConcept C61367390 @default.
• W3031578702 hasConcept C71924100 @default.
• W3031578702 hasConceptScore W3031578702C121608353 @default.
• W3031578702 hasConceptScore W3031578702C126322002 @default.
• W3031578702 hasConceptScore W3031578702C143998085 @default.
• W3031578702 hasConceptScore W3031578702C2776421732 @default.
• W3031578702 hasConceptScore W3031578702C2776551883 @default.
• W3031578702 hasConceptScore W3031578702C2780192828 @default.
• W3031578702 hasConceptScore W3031578702C29456083 @default.
• W3031578702 hasConceptScore W3031578702C61367390 @default.
• W3031578702 hasConceptScore W3031578702C71924100 @default.
• W3031578702 hasIssue "15_suppl" @default.
• W3031578702 hasLocation W30315787021 @default.
• W3031578702 hasOpenAccess W3031578702 @default.
• W3031578702 hasPrimaryLocation W30315787021 @default.
• W3031578702 hasRelatedWork W122177069 @default.
• W3031578702 hasRelatedWork W2414042649 @default.
• W3031578702 hasRelatedWork W2584454163 @default.
• W3031578702 hasRelatedWork W2765333766 @default.
• W3031578702 hasRelatedWork W2783882412 @default.
• W3031578702 hasRelatedWork W2917061290 @default.
• W3031578702 hasRelatedWork W2982156914 @default.
• W3031578702 hasRelatedWork W2996229517 @default.
• W3031578702 hasRelatedWork W3112466230 @default.
• W3031578702 hasRelatedWork W3217365879 @default.
• W3031578702 hasVolume "38" @default.
• W3031578702 isParatext "false" @default.
• W3031578702 isRetracted "false" @default.
• W3031578702 magId "3031578702" @default.
• W3031578702 workType "article" @default.